<bill session="110" type="s" number="2351" updated="2009-01-09T16:45:19-05:00">
	<status><introduced date="1195016400" datetime="2007-11-14"/></status>

	<introduced date="1195016400" datetime="2007-11-14"/>
	<titles>
		<title type="official" as="introduced">A bill to amend the Internal Revenue Code of 1986 to provide a tax credit for medical research related to developing qualified infectious disease products.</title>
	</titles>
	<sponsor id="300087"/>
	<cosponsors>
		<cosponsor id="300052" joined="2007-12-03"/>
	</cosponsors>
	<actions>
		<action date="1195016400" datetime="2007-11-14"><text>Read twice and referred to the Committee on Finance.</text></action>
	</actions>
	<committees>

	</committees>
	<relatedbills>

	</relatedbills>
	<subjects>

	</subjects>
	<amendments>

	</amendments>
	<summary>
	11/14/2007--Introduced.<br/>Amends the Internal Revenue Code to allow a general business tax credit for 50% of expenses paid for research and development of any qualified infectious disease product. Defines &quot;qualified infectious disease product&quot; as any antibiotic drug, antiviral, diagnostic test, biological product, or vaccine developed to treat, detect, prevent, or identify certain pathogens. Terminates such credit after 2012.<br/>
	</summary>
</bill>
